TY - JOUR T1 - A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines JF - medRxiv DO - 10.1101/2022.02.15.22270974 SP - 2022.02.15.22270974 AU - Sira Nanthapisal AU - Thanyawee Puthanakit AU - Peera Jaru-Ampornpan AU - Rapisa Nantanee AU - Pimpayao Sodsai AU - Orawan Himananto AU - Jiratchaya Sophonphan AU - Pintip Suchartlikitwong AU - Narin Hiransuthikul AU - Pornpimon Angkasekwinai AU - Auchara Tangsathapornpong AU - Nattiya Hirankarn AU - the study team Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/02/15/2022.02.15.22270974.abstract N2 - Background Immunogenicity of inactivated SARS-CoV-2 vaccine has waning antibody over time. With the emergence of the SARS-CoV-2 delta variant, which requires higher neutralizing antibody to prevent infection, a booster dose is needed.Objective To evaluate immunogenicity and reactogenicity of standard- versus low-dose ChAdOx1 nCoV-19 vaccine booster after CoronaVac in healthy adults.Methods A double-blinded, randomized, controlled trial of adult, aged 18-59 years, with completion of 2-dose CoronaVac at 21-28 days apart for more than 2 months was conducted. Participants were randomized to receive AZD1222 (Oxford/AstraZeneca) intramuscularly; standard dose (SD, 5×1010 viral particles) or low dose (LD, 2.5×1010 viral particles). Surrogate virus neutralization test (sVNT) against wild type and delta variant, and anti-spike-receptor-binding-domain IgG (anti-S-RBD IgG) were compared as geometric mean ratio (GMR) at day 14 and 90 between LD and SD arms.Results From July-August 2021, 422 adults with median age of 44 (IQR 36–51) years were enrolled. The median interval from CoronaVac to AZD1222 booster was 77 (IQR 64–95) days. At baseline, geometric means (GMs) of sVNT against delta variant and anti-S-RBD IgG were 18.1%inhibition (95%CI 16.4-20.0) and 111.5 (105.1-118.3) BAU/ml. GMs of sVNT against delta variant and anti-S-RBD IgG in SD were 95.6%inhibition (95%CI 94.3-97.0) and 1975.1 (1841.7-2118.2) BAU/ml at day 14, and 89.4%inhibition (86.4-92.4) and 938.6 (859.9-1024.4) BAU/ml at day 90, respectively. GMRs of sVNT against delta variant and anti-S-RBD IgG in LD compared to SD were 1.00 (95%CI 0.98-1.02) and 0.84 (0.76–0.93) at day 14, and 0.98 (0.94-1.03) and 0.89 (0.79-1.00) at day 90, respectively. LD recipients had significantly lower rate of fever (6.8%vs25.0%) and myalgia (51.9%vs70.7%) compared to SD.Conclusion Half-dose AZD1222 booster after 2-dose inactivated SARS-CoV-2 vaccination had non-inferior immunogenicity, yet lower systemic reactogenicity. Fractional low-dose AZD1222 booster should be considered especially in resource-constrained settings.Highlights- Low dose AZD1222 could boost comparable immunity to standard dose in healthy adult who completed 2 doses of inactivated SARS-CoV-2 vaccines.- Less reactogenicity occurred in low-dose AZD1222 booster than standard-dose recipients.HighlightsThai Clinical Trials Registry (thaiclinicaltrials.org): TCTR20210722003Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThai Clinical Trials Registry: thaiclinicaltrials.org, TCTR20210722003.Funding StatementThe study was funded by the Ratchadapisek Sompoch Endowment Fund (2021) under Health Research Platform (764002-HE07), Chulalongkorn University and Faculty of Medicine, Thammasat University. This research is also supported by Ratchadapisek Somphot Fund for Postdoctoral Fellowship, Chulalongkorn University.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional review board of Faculty of Medicine, Thammasat University (MTU-EC-PE1-182/64) and Faculty of Medicine, Chulalongkorn University (IRB No. 600/64) approved this study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.BAUBinding-antibody unitBMIBody mass indexCMICell-mediated immunityELISpotEnzyme-linked immunospotGMGeometric meanGMRGeometric mean ratioLDLow dosePBMCPeripheral blood mononuclear cellSFUSpot forming unitS-RBDSpike receptor binding domainSDStandard dosesVNTSurrogate virus neutralization test ER -